When compared with non-NAFLD-HCC patients, those with NAFLD-HCC had lower alpha-foetoprotein (AFP), lower classification for the primary tumour (T) and less common metastatic (M) disease leading to a less advanced stage of HCC (Table 2). This evidence concerns the gene AFP and metabolic dysfunction-associated steatotic liver disease.